Home
Sessions
Late-breaking Abstract Session
Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study

Sep 29

LBA 01 - Late-breaking Abstract Session

LBA 04 - Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study

02:45pm - 02:55pm ET

Presenter(s)

Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Lombardia